BLUE News and Press, bluebird bio Inc. From 04/14/21

bluebird bio (NASDAQ: BLUE) ran into some issues with manufacturing its gene therapy, and then the drugmaker was sideswiped by the possibility that its treatment might cause cancer. In this video from Motley Fool Live , recorded on Mar ch 22 , Fool.com contributo...

CRSP's leading investigational therapy CTX001's mode of action creates a situation where the company is killing two birds with one stone, treating both beta-thalassemia and sickle cell disease patients. Although the beta-thalassemia market size is small, the combined patient pool of S...

Top Health Care Stocks To Buy [Or Sell] Right Now Health care stocks continue to show long-term value for investors in the stock market . One of the reasons could be that health care is always in demand. Health care companies provide and sell a wide range of products aft...

Shares of bluebird bio (NASDAQ: BLUE) have been on a roller coaster ride recently as the company faced the potential that its gene therapy could cause cancer. In this video from Motley Fool Live , recorded on Mar ch 15 , Fool.com contributors Brian Orelli and Kei...

Should Investors Be Watching These Top Health Care Stocks Right Now? Most would know that health care stocks are amongst the top performers throughout the current pandemic. Some might even say that the sector is among the best to invest in now. For one thing, the industry is hom...

Universe Pharmaceuticals (UPC) +113%.Humanigen (HGEN) +61% on positive Phase 3 data for COVID-19 therapy.Cyanotech Corporation (CYAN) +48%.Big Rock Partners Acquisition (BRPA) +42%.SeaChange International (SEAC) +34% on multi-million-dollar contract with broadband service provider.F...

Vertex's shares represent an excellent investment opportunity based on the undervaluation of the current drug portfolio. If the VX-864 drug proves effective in the Phase 2 of clinical trials, it may become the closest driver for the growth of shares. There is significant long-term...

Bristol Myers Squibb (BMY) and bluebird bio (BLUE) announced the FDA approval for idecabtagene vicleucel (ide-cel) for a certain category of adult patients with relapsed or refractory multiple myeloma. The FDA authorization has come a day ahead of the action date.The approval f...

Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma 1 In the pivotal KarMMa trial, the majority (72%) of patients achieved rapid, deep and durable responses...

What do playing right field in baseball, deep-sea fishing, and investing in small biotech stocks have in common? Long periods of boredom followed by moments of intense drama. For shareholders of bluebird bio (NASDAQ: BLUE) , Sage Therapeutics (NASDAQ: SAGE) , and...